von Willebrand factor type D domain mutant of SVS-1/SUSD2, vWDm, induces apoptosis in HeLa cells

Cancer Science

Volumn 98, Issue 6, 2007, Pages 909-915

  Sugahara, Tetsuo ^a   Yamashita, Yzumi ^a   Shinomi, Masahito ^a   Isobe, Yumiko ^a   Yamanoha, Banri ^a   Iseki, Hiroyoshi ^b   Takeda, Akihiko ^b   Okazaki, Yasushi ^b,c   Kawai, Kenji ^d   Suemizu, Hiroshi ^d   Andoh, Toshiwo ^a  

^a SOKA UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^d CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; CASPASE 12; CASPASE 3; CASPASE 8; CASPASE 9; DNA FRAGMENT; MUTANT PROTEIN; PROTEIN KINASE B; PROTEIN SVS 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME ACTIVATION; GENETIC CONSERVATION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LASER MICROSCOPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL PROLIFERATION; HELA CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MUTANT PROTEINS; ONCOGENE PROTEIN V-AKT; PROTEIN STRUCTURE, TERTIARY; VON WILLEBRAND FACTOR;

EID: 34247863897     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00467.x     Document Type: Article

References (39)

1. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol Ther 2003; 2 (4 Suppl. 1): S115-21.
2. Hernandez-Alcoceba R, Sngro B, Prieto J. Gene therapy of liver cancer. World Gastroenterol 2006; 14: 6085-97.
3. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991; 253: 49-53.
4. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
5. Soussi T, Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 2001; 1: 233-40.
6. Kato S, Han SY, Liu W et al. Understanding the function-structure and function-mutation relationship of p53 tumor suppressor protein by high-resolution missense mutations analysis. Proc Natl Acad Sci USA 2003; 100: 8424-9.
7. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 2003; 100: 9934-9.
8. Soussi T, Kato S, Levy PP et al. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25: 6-17.
9. Nakamura Y, Futamura M, Kamino H, Yoshida K, Nakamura Y, Arakawa H. Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis. Cancer Sci 2006; 97: 633-41.
10. Ji L, Fang B, Yen N et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59: 3333-9.
11. Saeki T, Mhashilkar A, Swanson X et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558-66.
12. Roz L, Gramegna M, Ishii H et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA 2002; 99: 3615-20.
13. Tambe Y, Isono T, Haraguchi S et al. A novel apoptotic pathway induced by the drs tumor suppressor gene. Oncogene 2004; 23: 2977-87.
14. Sugahara T, Yamashita Y, Shinomi M et al. Isolation of a novel mouse gene, mSVS-1/SUSD2, reversing tumorigenic phenotypes of cancer cells in vitro. Cancer Sci 2007; doi: 10.1111/j.1349-7006.2007.00466.x.
15. Yanagihara M, Sasaki-Takahashi N, Sugahara T et al. Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/ or II and induce apoptosis by inactivation of Akt/protein kinase B. Cancer Sci 2005; 96: 816-24.
16. Colombatti A, Bonaldo P, Doliana R. Type A modules: Interacting domains found in several non-fibrillar collagens and in other extracellular matrix proteins. Matrix 1993; 13: 297-306.
17. Bork P. Shuffled domains in extracellular proteins. FEBS Lett 1991; 286: 47-54.
18. Hilbert L, Jorieux S, Proulle V et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 2003; 120: 627-32.
19. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005; 26: 2031-45.
20. Van Oijen MGCT, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000; 6: 2138-45.
21. Shieh SY, Ikeda M, Taya Y et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997; 91: 325-34.
22. Kakudo Y, Shibata H, Otsuka K et al. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005; 65: 2108-14.
23. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-42.
24. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-9.
25. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001; 98: 10 983-5.
26. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
27. Alessi DR, James SR, Downes CP et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7: 261-9.
28. Stephens L, Anderson K, Stokoe D et al. Protein kinase B kinases that mediate phosphatidylinositol 3-5-trisphosphate-dependent activation of protein kinase B. Science 1998; 279: 710-14.
29. Alessi DR, Deak M, Casamayor A et al. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): Structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 1997; 7: 776-89.
30. Dong LQ, Liu F. PDK2: The missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab 2005; 289: E187-96.
31. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
32. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005; 280: 40406-16.
33. Yang J, Cron P, Good VM et al. Crystal structure of an activated Akt/ protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002; 9: 940-4.
34. Zong WX, Li C, Hatzivassiliou G et al. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J Cell Biol 2003; 162: 59-69.
35. 2+: A control point for apoptosis. Science 2003; 300: 135-9.
36. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000; 150: 887-94.
37. Rao RV, Castro-Obregon S, Frankowski H et al. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 2002; 277: 21 836-42.
38. Fujiwara H, Yamakuni T, Ueno M et al. IC101 induces apoptosis by Akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with Akt in L1210 cells. J Pharmacol Exp Ther 2004; 310: 1288-95.
39. Fang B, Roth JA. Tumor-suppressing gene therapy. Cancer Biol Ther 2003; 2 (4 Suppl. 1): S115-21.